Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 4/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345099 | 0.85 | PRKCA (0.41) | EPHX1 | |
| SCHEMBL1345511 | 0.84 | KDM4E (0.39) | — | |
| SCHEMBL1344678 | 0.81 | SCNN1A (0.43) | DDAH1 | |
| SCHEMBL1344939 | 0.81 | SLC1A3 (0.45) | DDAH1 | |
| SCHEMBL1344948 | 0.81 | POLB (0.45) | DDAH1 | |
| SCHEMBL1343495 | 0.80 | ALDH1A1 (0.41) | DDAH1 | |
| SCHEMBL1345053 | 0.78 | FDFT1 (0.42) | — | |
| SCHEMBL1345420 | 0.75 | DDAH1 (0.47) | DDAH1 | |
| SCHEMBL1342933 | 0.74 | ADRB2 (0.42) | — | |
| SCHEMBL1343488 | 0.74 | DDAH1 (0.43) | DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828109-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL BUSINESS PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8063104-B2 | Guanidine derivatives as inhibitors of DDAH | UCL BUSINESS PLC (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | CTSD 2337/4885P2RX7 3743/4885EPHX1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.